FDA blocks vaccine safety studies

Vaccine safety research is supposed to do one basic job — check huge real-world datasets for rare problems, then let outside scientists argue over the results in public. That process broke here. In October 2025 and February 2026, FDA leaders stopped or delayed publication of several agency-linked studies on COVID-19 vaccines and GSK’s shingles shot, Shingrix, even though the underlying analyses largely pointed to rare side effects and favorable safety profiles. The official explanation is that the papers reached too far beyond the data. The reason this turned into a real story is that blocking publication is different from criticizing a paper after it appears. (cnbc.com) ### What exactly got blocked? Two COVID-19 vaccine studies that had already been accepted by medical journals were pulled back in October, and abstracts tied to Shingrix research were not cleared for a drug-safety conference in February. The studies were done by FDA scientists working with outside data firms and drew on millions of patient records. (cnbc.com)? One study looked at vaccine safety in older adults and checked 14 outcomes that could plausibly be linked to vaccination. It reportedly found one clear signal — anaphylaxis after Pfizer’s Comirnaty — and no other statistically significant risk increases. A second study covering people from 6 months to 64 years old found some rare fever-related seizu(cnbc.com)the risks. (fiercepharma.com) ### And the shingles study? The public reporting is thinner there, but the blocked Shingrix work appears to have supported the shot’s safety or effectiveness rather than raising a new alarm. HHS said that study’s design “fell outside the agency’s purview,” which is a narrower and slightly different objection than the one used for the COVID papers. That d(fiercepharma.com)the studies. (cnbc.com) ### Why does publication matter so much? Because publication is how scientific claims get stress-tested. A paper in a journal or an abstract at a conference is not the final word, but it gives other researchers something concrete to inspect, criticize, replicate, or rebut. Blocking release upstream is more like stopping the game before replay review. You never get the public argument that normally tells you whether the conclusions were too broad or perfectly fair. (cnbc.com) ### What is HHS saying? HHS spokesperson Andrew Nixon said the studies were withdrawn because the authors drew broad conclusions not supported by the underlying data, and said FDA was protecting the integrity of its scientific process. That is a real kind of scientific dispute. The catch is that outside researchers cannot evaluate that claim properly if the work stays unseen. (cnbc.c([cnbc.com)y are people reading this politically? Because this did not happen in isolation. Under HHS Secretary Robert F. Kennedy Jr., federal health agencies have already softened some COVID vaccine recommendations, cut back parts of vaccine research, and faced separate criticism over pausing other vaccine-related publications. So even if the narrow dispute is methodological, the broader pattern makes scientists worry that only results fitting leadership’s priors will move. (cnbc.com) ### Is this proof the vaccines are risk-free? No — and that is not what the blocked studies seem to have said anyway. Vaccines can have rare side effects, including myocarditis in some groups and severe allergic reactions in very uncommon cases. The issue here is not whether risk exists. Basically, it is whether the government should suppress analyses that mostly reinforce the existing view that the benefits still exceed those risks. (fiercepharma.com) ### What’s the bottom line? The FDA did not uncover a hidden vaccine danger here. It stopped several safety analyses from reaching the normal scientific arena. Maybe the conclusions really were overstated. But until the agency releases the work, the public is being asked to trust a censorship decision instead of a transparent argument. (cnbc.com)